Date: 2014-12-19
Type of information: Resignation
Compound:
Company: Alnylam Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On December 19, 2014, Alnylam Pharmaceuticals , a leading RNAi therapeutics company, announced that Laurence Reid , Ph.D., the company\'s Chief Business Officer, plans to resign from the company, effective December 31, 2014 . Dr. Reid will be joining Third Rock Ventures (TRV) as an Entrepreneur-in-Residence, and is expected to become a Chief Executive Officer for a TRV portfolio company in the future. Alnylam will initiate an external search to identify a new Chief Business Officer.
Financial terms:
Latest news:
